Acrodermatitis continua of Hallopeau with insufficient response to ixekizumab and infliximab, successfully treated with a combination of ustekinumab and tofacitinib

Eur J Dermatol. 2023 Apr 1;33(2):182-183. doi: 10.1684/ejd.2023.4461.
No abstract available

MeSH terms

  • Acrodermatitis* / drug therapy
  • Exanthema*
  • Humans
  • Infliximab / therapeutic use
  • Ustekinumab

Substances

  • ixekizumab
  • Ustekinumab
  • tofacitinib
  • Infliximab